Knight Therapeutics (TSE:GUD) Trading Down 0.2% – Here’s What Happened

Knight Therapeutics Inc. (TSE:GUD)’s stock price traded down 0.2% on Friday . The stock traded as low as C$5.96 and last traded at C$5.97. 8,702 shares changed hands during trading, a decline of 85% from the average session volume of 59,920 shares. The stock had previously closed at C$5.98.

Knight Therapeutics Price Performance

The firm has a market capitalization of C$592.76 million, a P/E ratio of -149.25, a P/E/G ratio of -1,013.50 and a beta of 0.06. The business’s fifty day moving average is C$6.00 and its 200 day moving average is C$6.08. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52.

Knight Therapeutics (TSE:GUD) last issued its earnings results on Thursday, November 6th. The company reported C($0.04) earnings per share for the quarter. The business had revenue of C$122.63 million for the quarter. Knight Therapeutics had a negative return on equity of 4.04% and a negative net margin of 8.81%. As a group, analysts forecast that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.